Yaz plus

Quick links to important sections

Yaz plus

Selected form

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Yaz plus

Quick Facts

Property Description
Active Ingredients Drospirenone, Ethinyl Estradiol, Levomefolate Calcium
Form Film-coated tablets (Oral)
Pharmacological Class Combined Oral Contraceptive; Folate Supplement
Common Use Pregnancy prevention
Origin Synthetic/Derived

Yaz plus: What Kind of Combination Pill Is It? (Definition & Classification)

Yaz plus is a prescription-only, oral combination contraceptive medication, supplied as a film-coated tablet taken by mouth. It is classified as a hormonal contraceptive that includes a folate supplement. Its full generic name is Drospirenone/Ethinyl Estradiol/Levomefolate Calcium.

This medication is an example of a widely prescribed combined oral contraceptive (COC), a method clinically recognized for its high efficacy in preventing pregnancy. These hormonal contraceptives are generally recognized as a reliable method for pregnancy prevention when used correctly. This type of formulation is often selected for women seeking not only birth control but also potential symptomatic benefits.

What Are the Unique Ingredients in Yaz plus? (Composition & Formulation)

Yaz plus contains three active ingredients: the estrogen Ethinyl Estradiol, the progestin Drospirenone, and the vitamin Levomefolate Calcium. The hormones are synthetic, while the Levomefolate Calcium is a derived, active B vitamin. This three-part composition differentiates it from standard two-component birth control pills.

The most distinctive feature is the progestin, Drospirenone. This compound is structurally similar to a common diuretic, giving it mild properties that can help counteract the fluid retention sometimes associated with other hormonal methods. The inclusion of the active folate component, Levomefolate Calcium, positions it specifically toward patients who value nutritional support alongside contraception.

What Is the General Purpose of Yaz plus? (Purpose & High-Level Benefit)

The fundamental purpose of Yaz plus is highly effective pregnancy prevention. Beyond this, the unique formulation is frequently used to manage symptoms related to hormonal fluctuation, such as achieving clearer skin in women with moderate hormonal acne. Furthermore, the active folate component serves a prophylactic (preventative) purpose, helping ensure women maintain adequate folate status.

What side effects are possible with Yaz plus?

Possible Side Effects and Safety Information

Official regulatory documents emphasize specific safety information for Yaz plus (drospirenone and ethinyl estradiol, plus levomefolate calcium) to inform patients about its risk profile, which is primarily structured around the potential for serious cardiovascular and thromboembolic events.

Serious Safety Risks and Contraindications

The most serious risk, highlighted by a Boxed Warning, involves the potential for life-threatening blood clots (thrombosis) in veins or arteries, which may lead to deep vein thrombosis, pulmonary embolism, myocardial infarction, or stroke. This risk is highest during the first year of use or upon restarting after a break of four weeks or more.

Due to the anti-mineralocorticoid activity of the drospirenone component, there is a risk of hyperkalemia (elevated potassium levels). The medicine is strictly contraindicated for patients with kidney, liver, or adrenal disease, and those taking other medications that increase potassium, requiring mandated potassium monitoring in these cases.

Use is also prohibited in women who smoke and are over 35, and in patients with specific pre-existing conditions, including certain cancers, uncontrolled hypertension, diabetes with vascular involvement, or a history of heart attack, stroke, or deep vein thrombosis.

Common Adverse Reactions

Adverse reactions that are commonly reported in clinical trials include headache, nausea, breast tenderness, and menstrual irregularities (e.g., intermenstrual bleeding or spotting).

Overdose and Emergency Response

Overdose and when to seek help: Official Regulatory Information

The regulatory profile for Yaz plus (Drospirenone/Ethinyl Estradiol/Levomefolate Calcium) documents specific findings and management requirements for overdosage.

Documented Manifestations and Outcomes

Overdosage is formally documented to cause expected hormonal effects, primarily nausea and withdrawal bleeding in females. Official prescribing information indicates that acute overdosage of the contraceptive components, including ingestion by children, has not been associated with reports of serious ill effects. The Levomefolate Calcium component does not typically contribute to toxicity in overdose situations.

Required Emergency Actions and Monitoring

Due to the anti-mineralocorticoid properties of the Drospirenone component, any suspected overdosage requires seeking immediate medical attention. This action is mandated because the regulatory management of overdosage necessitates specialized clinical monitoring for potential, though rare, serious metabolic and electrolyte imbalances.

Management is symptomatic and supportive, as no specific antidote is known. Essential monitoring requirements include checking the serum concentration of potassium and sodium and testing for evidence of metabolic acidosis. These steps are required to mitigate the risk of severe complications. Contacting a poison control center immediately is also a necessary action in suspected overdose situations, aligning with official guidelines.

Therapeutic Uses of Yaz plus

The therapeutic purpose of this formulation is multifaceted; it is used for reliable pregnancy prevention and for symptomatic management. This medication is commonly used across conditions presenting with episodic or fluctuating manifestations, relevant in contexts marked by increased discomfort.

It is applied in addressing conditions that include: Premenstrual Dysphoric Disorder (PMDD), moderate acne vulgaris, and the need for folate status support. The combination may assist with managing symptom clusters that may become intense or disruptive, such as severe cyclical mood swings and hormone-driven breakouts. It is relevant for easing symptoms related to heightened physiological activity and may help patients cope more steadily with symptom fluctuations. The use of the medication helps maintain a sense of stability when symptoms are more noticeable.


Quick Fact: Symptomatic Support
Symptom Domains Severe cyclical irritability, bloating, and moderate acne breakouts
Main Benefit Supports stability during premenstrual episodes
Context Applied when symptoms interfere with daily comfort
Additional Use Folate status maintenance for reproductive health

Eligibility and Restrictions for Use

Who Can and Cannot Use Yaz plus?

The population eligibility for Yaz plus (Drospirenone/Ethinyl Estradiol/Levomefolate Calcium) is strictly defined by government regulatory documents, focusing on conditions that present an increased health risk. Use is established for females of reproductive potential who have achieved menarche.


Contraindications: Populations Who Must Not Use Yaz plus

The medicine is absolutely contraindicated in women presenting with severe cardiovascular, thrombotic, or organ function issues. This includes women over 35 who smoke and those with a current or history of thrombotic/thromboembolic events (e.g., DVT, stroke, MI). It is also contraindicated in patients with severe hepatic disease, severe renal insufficiency, or adrenal insufficiency.


Restricted and Special Population Use

Condition/Population Regulatory Status/Restriction
Pregnancy Contraindicated (Must be ruled out prior to initiation).
Lactation/Breastfeeding Not recommended (Due to potential excretion in milk).
Geriatric Use Not indicated (Not for postmenopausal women).
Major Surgery/Immobilization Must be stopped at least 4 weeks before and 2 weeks after surgery.
Adolescents Only permissible after achieving menarche.

These constraints establish the strict regulatory boundaries for safe population use.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Interactions involving Yaz plus are defined by two primary regulatory domains: modification of plasma hormone levels (pharmacokinetics) and the physiological potentiation of potassium elevation (pharmacodynamics).

Officially Contraindicated Combinations

Classification Interacting Agents
Hepatitis C Regimen Medicinal products containing Ombitasvir/Paritaprevir/Ritonavir, with or without Dasabuvir [FDA].
Condition/Substance Smoking in women 35 years old [FDA].

Interactions Altering Hormone Levels

The hormonal components, Drospirenone and Ethinyl Estradiol, are substrates of the hepatic CYP3A4 enzyme system. Substances that are strong CYP3A4 inducers (e.g., Rifampin, Phenytoin, Carbamazepine, St. John's Wort) are documented to decrease the concentration of the hormones, potentially reducing efficacy. Conversely, strong CYP3A4 inhibitors (e.g., Itraconazole, Ketoconazole) are documented to increase the systemic exposure of the hormonal components [NIH].

Pharmacodynamic and Folate Interactions

Drospirenone possesses antimineralocorticoid activity. This creates an additive pharmacodynamic interaction risk when co-administered with other drugs that increase serum potassium levels, such as ACE inhibitors, Potassium-Sparing Diuretics, and NSAIDs (chronic use). Monitoring of serum potassium is recommended for at-risk patients on long-term treatment with these agents [EMA]. Additionally, the efficacy of the Levomefolate Calcium component may be reduced by medications that interfere with folate metabolism, including certain antiepileptics [MedlinePlus].

Mechanism of Action

Central Suppression of the Ovulatory Cascade

Yaz Plus primarily works by utilizing a combination of synthetic hormones to create negative feedback on the hypothalamic-pituitary-ovarian (HPO) axis. This action suppresses the pituitary release of gonadotropins (LH and FSH), preventing the development of a dominant follicle and the inhibition of ovulation, which is the core mechanistic consequence leading to anovulation.


Modulating Local Reproductive Tract Environments

The hormonal components also exert progestational effects on target tissues, including the endometrium and cervical mucus. This alters signaling sequences to thin the endometrial lining and increase the viscosity of cervical secretions. The altered viscosity creates a localized barrier effect, influencing sperm migration and endometrial receptivity.


Targeted Receptor Antagonism of Drospirenone

Drospirenone engages mechanisms outside the primary contraceptive pathway by acting as an antagonist at the Mineralocorticoid Receptor (MR) and the Androgen Receptor (AR). This targeted receptor interference influences fluid balance pathways and modulates the effects of androgens. The receptor antagonism modulates key regulatory systems involved in fluid dynamics and androgen response.


Providing Active Folate Substrate

The Levomefolate Calcium component is an active form of folate that supports essential metabolic pathways (e.g., DNA synthesis and repair). Its mechanism is one of biochemical supplementation, providing substrate for enzymatic reactions independent of hormonal action. This supports metabolic pathways dependent on single-carbon transfer.

Dosage and Administration Information

How to Use Yaz plus: Official Administration Guidelines

Administration Scope

The administration of Yaz plus (drospirenone/ethinyl estradiol/levomefolate calcium) is based on a fixed-dose, 28-day cycle that requires strict adherence to specific instructions for proper use.

Administration Detail Official Labeled Instruction
Route of Administration Oral (taken by mouth).
Dosing Schedule One fixed-dose tablet is taken daily for 28 consecutive days. The dose is not titrated.
Timing in Relation to Meals Can be taken with or without regard to meals.
Age-Group Rules Use for moderate acne is limited to women at least 14 years of age who have achieved menarche and desire oral contraception.

Procedural Structure and Timing

Use is continuous and cyclical, involving two types of film-coated tablets taken sequentially in a precise 28-day regimen. The regimen consists of 24 active pink tablets (containing all three active ingredients) followed immediately by 4 light orange folate tablets (hormone-free).

Special procedural conditions include the requirement that the tablet must be taken at the same time every day and in the exact order directed on the blister pack. The next 28-day pack must be started the day immediately following the last tablet of the previous pack, without skipping days.

Official protocols also exist for the management of missed doses, which specify the course of action based on the number of tablets missed and the week of the cycle they were missed. Severe gastrointestinal disturbances, such as vomiting or diarrhea within 3 to 4 hours of taking an active tablet, require following the missed-dose instructions.

Recent Clinical Evidence

Evidence for Use in Pregnancy Prevention (Contraception)

Research for contraception relies on large-scale Randomized Controlled Trials (RCTs) and observational studies. The primary outcome examined is the Pearl Index, a statistical measure tracking the number of pregnancies observed per 100 women-years of use. Studies reported measurements of a low Pearl Index. A recognized element in the efficacy analysis is the potential influence of patient adherence during the study, as observed outcomes rely on perfect and consistent use.


Evidence for Management of Premenstrual Dysphoric Disorder (PMDD)

Research on PMDD was conducted through short-term Randomized, Double-Blind, Placebo-Controlled Trials (RCTs). Researchers examined outcomes related to systemic imbalance, including changes in PMDD symptoms across emotional and physical domains. Some trials described patterns of measurement differences in symptom scores compared to the placebo group, but findings also indicated a notable placebo response rate. Research explored symptom changes only over three menstrual cycles, meaning long-term maintenance is not well characterized.


Evidence for Use in Moderate Acne Vulgaris Research

The research base for moderate acne was established in RCTs that monitored changes in acne lesion counts and evaluated overall skin appearance using the Investigator Global Assessment (IGA) score. Studies reported patterns in the measured outcomes over the six-cycle research period compared to placebo. Follow-up durations were limited to six menstrual cycles, and the research population was strictly limited to women who desire an oral contraceptive.


Evidence for Folate Status Support

Research for the folate component relied on specialized Pharmacokinetic/Pharmacodynamic (PK/PD) studies that monitored relevant biomarkers, such as red blood cell (RBC) folate concentrations. Studies reported measurements of increases in these biomarkers, showing patterns related to the accumulation of the compound. A key limitation is that no specific clinical trial was conducted to directly evaluate the relationship between using this combined product and the incidence of neural tube defects (NTDs); the outcome relies on extrapolation from general folate supplementation research.

Frequently Asked Questions (FAQ)

Common questions about Yaz plus (FAQ)


Q: How does Yaz plus compare to regular Yaz?

A: Yaz plus is a specific formulation that contains three active ingredients: the hormones drospirenone and ethinyl estradiol, plus Levomefolate Calcium, which is an active form of folate (a B vitamin). This inclusion of active folate is the primary difference from standard Yaz, which contains only the two hormonal components.


Q: How soon after starting Yaz plus can I expect it to start working?

A: If the medication is started later than the first day of your menstrual cycle, official product information states that non-hormonal back-up contraception is required for the first 7 consecutive days of taking the active tablets. This is to help ensure the medication has enough time to establish its contraceptive effect.


Q: What happens if I miss a pill while using Yaz plus?

A: Official guidelines provide specific instructions for managing a missed dose, and the required action depends on the number of tablets missed and the week of the cycle this occurs. Regulatory instructions for managing missed doses describe the need for additional non-hormonal contraception for a period if two or more active pills are missed.


Q: How long does it typically take for side effects to go away after starting Yaz plus?

A: Many individuals experience side effects, such as spotting or breakthrough bleeding, as their body adjusts to the medication. According to official product information, these effects often decrease or may resolve during the first few months of use. Evaluation by a healthcare provider is noted as appropriate if side effects persist or are severe.


Q: How does Yaz plus affect existing thyroid conditions?

A: The ethinyl estradiol component in the medication may increase the body's need for thyroid hormone. If an individual is taking levothyroxine (a thyroid hormone replacement), official guidance suggests that a healthcare provider may need to monitor thyroid hormone levels when starting or stopping this oral contraceptive.


Q: Can Yaz plus affect fertility after stopping the medicine?

A: Studies and official information indicate that the return of natural fertility for most women after stopping a combined oral contraceptive is rapid. The hormones stop ovulation while using the pill, but this effect reverses soon after discontinuation, consistent with general expectations for this type of medication.


Q: Can Yaz plus affect my mood or cause depression?

A: Depression is listed as an adverse reaction associated with this type of medication in official labeling. Regulatory information advises careful observation for women with a history of depression, and notes that the medication may be discontinued if depression recurs to a serious degree.


Q: What happens if I decide to stop taking Yaz plus?

A: Upon stopping the medication, the body's natural ovulatory cycle typically resumes. If the medicine was used to manage conditions like acne or PMDD, those symptoms may return. If the avoidance of pregnancy is desired after stopping the medication, the use of alternative contraception is described as necessary.


Q: Is it considered safe to switch directly from a different birth control to Yaz plus?

A: Official guidance specifies that the starting procedure involves initiating Yaz plus on the same day that a new pack of the previous oral contraceptive would have been started. This continuity helps maintain contraceptive protection.


Q: Are there any long-term side effects associated with Yaz plus?

A: Official documents highlight the risk of serious cardiovascular and thromboembolic events, such as blood clots, which can lead to severe health issues. These serious risks are structured as warnings, and the risk is highest during the first year of use or upon restarting after a break.


Q: Is Yaz plus safe to use if I have a history of migraines?

A: Regulatory information notes that a significant change in headaches warrants evaluation. Certain types of migraines, particularly those with aura, are considered contraindications for combined hormonal contraceptives due to an increased risk of stroke.


Q: What happens to my menstrual cycle while I am taking Yaz plus?

A: The cycle involves 24 days of active tablets followed by 4 hormone-free tablets. During the hormone-free days, a withdrawal bleed (similar to a period) is expected. The medication may also lead to the bleeding being lighter and more regular than a natural cycle.


Q: Does Yaz plus eliminate periods completely?

A: While a withdrawal bleed is typically expected during the hormone-free days, official labeling addresses the possibility of amenorrhea (missed periods). In cases where two or more expected withdrawal bleeds are missed, the official labeling notes that further evaluation is appropriate.


Q: Is it normal to have spotting or breakthrough bleeding when starting Yaz plus?

A: Yes, irregular menstrual periods, spotting, or breakthrough bleeding are commonly reported adverse reactions, especially during the first few months. This often occurs as the body adjusts to the hormonal regimen.


Q: Are there specific vitamins or supplements that interact with Yaz plus?

A: Regulatory documents indicate that substances that affect the CYP3A4 enzyme system in the liver, such as the herbal supplement St. John’s Wort, may decrease the concentration of the hormones, potentially reducing efficacy. Additionally, the folate component can be affected by certain medications that interfere with folate metabolism.


Q: Does Yaz plus influence cholesterol levels?

A: Official documents state that combined oral contraceptives may have metabolic effects on lipids (fats in the blood). For women with conditions such as uncontrolled dyslipidemia (high cholesterol or fats in the blood), regulatory documents note that monitoring may be appropriate.


Q: Does alcohol consumption affect how Yaz plus works?

A: While official warnings do not typically note a direct chemical interaction with alcohol, heavy consumption may be associated with increased instances of vomiting or forgotten doses, which can indirectly reduce the contraceptive effectiveness of the pill.


Q: What information is available about the safety of Yaz plus for teenagers?

A: Safety and efficacy for this type of combined oral contraceptive have been established in women of reproductive age. Efficacy is expected to be the same for postpubertal adolescents (those who have started their periods) under 18 as it is for adults. The medication is not indicated for use before menarche.

How should Yaz plus be stored and disposed of?

Official Storage and Disposal Requirements

Official regulatory documents define specific conditions for storing and disposing of Yaz plus to maintain its stability and ensure environmental safety.

Mandatory Storage Conditions

Requirement Details
Temperature Store between 15 C and 25 C (some labels allow up to 30 C).
Protection Must be protected from moisture, heat, and direct sunlight.
Packaging Keep the medicine in its original pouch and carton until use.
Safety Must be kept out of reach of children and pets.

Official Disposal Rules

  • The medicine should not be disposed of via household waste or by flushing down a toilet or sink.
  • Unused or expired medication must be returned to a pharmacist or collected via an authorized medicine take-back program. These measures help to protect the environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Yaz plus found in:

A-Z Index: